Media stories about Ultragenyx Pharmaceutical (NASDAQ:RARE) have been trending somewhat positive on Monday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.15038164642 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $53.80 on Monday. Ultragenyx Pharmaceutical has a one year low of $41.67 and a one year high of $88.95. The company has a market cap of $2,670.00, a price-to-earnings ratio of -9.82 and a beta of 1.93.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.00) by ($0.27). The company had revenue of $2.41 million for the quarter, compared to analyst estimates of $0.75 million. During the same period last year, the firm posted ($1.75) earnings per share. analysts anticipate that Ultragenyx Pharmaceutical will post -6.25 earnings per share for the current year.

A number of research firms have weighed in on RARE. Zacks Investment Research downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. BidaskClub downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. Robert W. Baird reaffirmed a “buy” rating and set a $70.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 23rd. Canaccord Genuity set a $80.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and issued a $66.00 target price (down previously from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $68.94.

WARNING: “Ultragenyx Pharmaceutical (RARE) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/12/ultragenyx-pharmaceutical-rare-receiving-somewhat-favorable-media-coverage-analysis-finds.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.